iCAD Management

Management criteria checks 2/4

iCAD's CEO is Dana Brown, appointed in Mar 2023, has a tenure of 1.08 years. directly owns 0.19% of the company’s shares, worth $82.00K. The average tenure of the management team and the board of directors is 1 years and 3.9 years respectively.

Key information

Dana Brown

Chief executive officer

US$120.8k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	0.2%
Management average tenure	1yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

CEO

Dana Brown (58 yo)

1.1yrs

Tenure

US$120,848

Compensation

Ms. Dana R. Brown was Independent Director of iCAD, Inc. from January 10, 2022 until January 2023 and serves as its Executive Chair from January 2023 and also serves as its President and Chief Executive Of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dana Brown	President	1.1yrs	US$120.85k	0.19% $ 82.0k
Jonathan Go	Chief Technology Officer	5.3yrs	US$405.13k	0.72% $ 302.0k
Eric Lonnqvist	Chief Financial Officer	less than a year	no data	no data
Michelle Strong	Chief Operations Officer	less than a year	no data	no data
Annette Heroux	Vice President of Administration	no data	US$177.53k	no data
Anthony Takazawa	Director of Investor Relations	no data	no data	no data
Brian Testa	Chief People Officer	2.8yrs	no data	no data
Bill Keyes	Senior VP of Global Sales Operations	1.3yrs	no data	no data
Vasu Avadhanula	Chief Product Officer	less than a year	no data	no data
Peter Graham	Senior VP of North American Sales	less than a year	no data	no data

1.0yrs

Average Tenure

60yo

Average Age

Experienced Management: ICAD's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Dana Brown	President	2.3yrs	US$120.85k	0.19% $ 82.0k
Michael Doyle	Director	less than a year	no data	0.00020% $ 84.3
Susan Wood	Independent Director	5.6yrs	US$161.01k	0.016% $ 6.6k
Andrew Sassine	Independent Director	8.3yrs	US$163.51k	4.55% $ 1.9m
Stamatia Destounis	Member of Medical Advisory Board	no data	no data	no data
Robert Nishikawa	Member of Medical Advisory Board	no data	no data	no data
Kathy Schilling	Member of Medical Advisory Board	no data	no data	no data
Emily Conant	Member of Medical Advisory Board	no data	no data	no data
Hedvig Hricak	Director	less than a year	no data	no data
Per Hall	Member of Medical Advisory Board	no data	no data	no data
Rakesh Patel	Independent Director	5.6yrs	US$152.01k	0.24% $ 99.5k
Linda Moy	Member of Medical Advisory Board	no data	no data	no data

3.9yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ICAD's board of directors are considered experienced (3.9 years average tenure).

iCAD Management

Management criteria checks 2/4

Key information

Recent management updates

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

Executive Chair recently bought US$52k worth of stock

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Recent updates

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD, Inc. to Report Q4, 2021 Results on Feb 28, 2022

iCAD: Downside Seems Limited

Consensus EPS estimates fall by 11%

iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially

Price target decreased to US$19.43

Forecast breakeven date pushed back to 2024

iCAD, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021 and for the Full Year 2021

iCAD, Inc. announces First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

Executive Chairman & CEO recently bought US$99k worth of stock

Price target decreased to US$21.43